The successful utility of targeting IL‐4Rα signaling has led to clinical trials for dupilumab, a human monoclonal antibody for anti‐TH2 therapy in allergic asthma patients and atopic dermatitis.12, 13, 58 Concern arises on unprecedented TH1/TH17 polarizing inflammation with anti‐TH2 interventions in humans and mice.4, 24, 25, 27, 59, 60 Our mouse model clears a TH2 response without inducing any potential TH1/TH17 responses even with established disease, thus emphasizing on a potential benefit of anti‐IL‐4Rα therapies as a viable TH2 treatment option. The gene discussed is IL4R; the disease is allergic asthma.